Welcome to BioSuperior Insights
Find out more about lung disease and BioSuperior related topics.
BioSuperior FAQ
We are answering the most common questions asked about BioSuperior in our latest FAQ.
Why New Lung Surfactants Are Still Sorely Needed
Premature birth is a major health concern that can result in death or significant disability. While it has long been known that dysfunctional lungs are of major importance, it wasn’t until Dr. Mary Ellen Avery set out to understand the disease that we came to...
BioSuperior Technology Infographic
We've added an infographic that shows the scope and scale of lung disease, as well as the expertise and solutions BioSuperior Technology is bringing to the market. Find out more.
Advances in Genomics and Data Analytics at the PMWC 2022 Symposium will Help Propel the Development of Innovative Treatments for Serious Lung Disease
Dr. Ehud Goldin and I attended the 2022 Precision Medicine World Conference last week. The emphasis of this meeting concerned genomics and data analytics. While many of the advances can benefit respiratory medicine, most of the attention at this meeting was focused on...
RESI investor meetings continue to provide a great platform for startups like BioSuperior Technology
My meetings at the January 2022 RESI Conference were dedicated to introducing BioSuperior Technology. At the June RESi Conference my meetings were a mix of introductions and updates. I was excited to share the progress we have made during the first half of 2022! While...
Insight from NSF I-Corps Program Highlights Critical, Unmet Need In Treating Lung Disease
On their website, the National Science Foundation’s Innovation Corps (I-Corps™) states that their program “uses experiential education to help researchers gain valuable insight into entrepreneurship, starting a business or industry requirements and challenges. I-Corps...
ATS 2022 Confirmed An Exciting Outlook For BioSuperior Technology
Last week’s Research Innovation Summit, which is part of ATS 2022, was a great opportunity to network and learn perspectives from industry experts. I was excited to be there! I looked forward to talking with other companies who are developing lung therapeutics and...